Skip to main content

Table 1 Selected migraine drug development programs (compiled from http://www.clinicaltrials.gov).

From: Migraine pathogenesis and state of pharmacological treatment options

Drug

Mechanism of action

Stage of development

Acute attack

Telcagepant (MK-0974)

CGRP receptor antagonist

Phase III- complete

BI 44370

CGRP receptor antagonist

Phase II

COL-144

5-HT1F receptor agonists

Phase II

SB-705498

TRPV1 receptor antagonists

Phase II

BGG492

AMPA receptor antagonist

Phase II

Tezampanel (LY-293558)

AMPA and kainate receptor antagonist

Phase II

LY466195

GLUK5 kainate receptor antagonists

Phase II

NPS 1776

Anticonvulsant

Phase II

BGC20-1531

Prostanoid EP4 receptor antagonist

Phase II

NXN-188

nNOS inhibition and 5-HT1B/D agonist

Phase II

Preventives

Ramelteon

Melatonin MT1 and MT2 receptor agonist

Phase IV

Botulinum Toxin type A

Unknown

Phase III

Tonabersat

Gap junction/CSD inhibitor

Phase II- failed in migraine without aura

ADX10059

mGluR5 Modulator

Phase II

Perampanel (E2007)

AMPA receptor antagonist

Phase II

GW274150

iNOS

Phase II- failed

Carisbamate (RWJ-333369)

Anticonvulsant

Phase II- failed

  1. CGRP, calcitonin gene-related peptide; CSD, cortical spreading depression; nNOS, nitric oxide synthase; iNOS, inducible nitric oxide synthase